Bret Laczynski Brain Cancer Research Fund

Directions Website

Bret Laczynski Brain Cancer Research Fund On September 28, 2002, our son Bret was diagnosed with a very aggressive high risk Medulloblastoma at the age of 10 years old. The Ann & Robert H.

This is Bret's Story

Bret was like any other normal healthy 10 year old boy just starting the 4th grade. He was always a straight “A” student, favorite sports to play were soccer and golf and he was a diehard Cubs fan! Although Bret was a very shy boy by nature, once he felt comfortable with you, he loved to make you laugh with his one-of-kind sense of humor. You would have never thought that this handsome little blonde- haired, green-eyed boy was about to face the biggest fight that no child should ever have to.
Bret completed a total of 13 days into the school year when he started to experience unexplainable symptoms such as, vomiting for no apparent reason, extreme tiredness, neck pain, an unsteady gait and finally double-vision. About 4 weeks passed of pediatricians not having any answers, so we took him to the emergency room near our home in Indiana. On September 28, 2002, a CT Scan revealed a golf ball size mass in the fourth ventricle of his brain. An emergency surgery was performed that night to relieve the pressure (hydrocephalus) building up around his brain. We were told that due to the severity of his condition, Bret would need to be cared for by pediatric specialists.
There was no time to even absorb what was actually happening to our son, a decision had to be made and fast. Lurie Children’s Hospital of Chicago (or formerly Children’s Memorial Hospital as we knew it then) is known all over the country as one of the top children’s hospitals in the world, and it is where we wanted him to be. Bret was airlifted the next day by Children’s Transport Team. We were greeted by the top physicians in their fields, Dr. Stewart Goldman (Hematology/Oncology) and Dr. Tadanori Tomita (Neurosurgery). An MRI determined our worst nightmare, Stage 4 Medulloblastoma brain cancer. Surgery was performed 3 days later to resect the tumor. As if things couldn’t have gotten any worse, the tumor had metastasized to the entire surface of his brain. We were given the very aggressive course of treatment plan, but were also told that Bret was not expected to survive. How, as parents, do you even begin to explain this to your very sick little boy, when we don’t understand it ourselves? So Dr. Goldman stepped up and very graciously explained to Bret, in only words a child could understand. His response was simply, “ok”. And so it began.
Bret was to begin a six week regimen of brain and spinal radiation, followed by fourteen months of chemotherapy. All of that was halted when Bret starting seizing uncontrollably. In order to stop the seizures, he had to be put in a drug induced sleep with monitored anti-convulsant medications. It was then that he had a very dangerous allergic reaction to one of the medications

and developed yet another life-threatening condition called Stevens Johnsons. He was in the PICU for about 3 weeks until the rash cleared up and he was finally able to begin his treatments. Because he was still considered unstable, they transported him everyday, for the entire six weeks, by ambulance to Northwestern Memorial Hospital. Once chemotherapy began, it was about 4 months before Bret was finally able to go home.
He wasn’t home for more than a few days at a time, because the chemotherapy side effects were bringing him right back to the hospital. Many surgeries, line infections and low counts kept us coming for about the first 2 years of his illness. He was only able to complete about 7 months of chemotherapy as we almost lost him twice due to the aggressiveness of the treatments. With Dr. Goldman’s advice, we had to stop treatments and hope for the best. Bret defied all odds and as time went on, he was well enough to attend a school for children with disabilities. The Special Education Learning Facility (S.E.L.F.) of Valparaiso, IN welcomed Bret with open arms. Because Bret experienced so much trauma to his brain, he was developmentally delayed, suffered apraxia (oral motor difficulties limiting feeding), aphasia (limited communication), seizure disorder, adrenal insufficiency and hypothyroidism, just to name a few. You would expect someone faced with so many challenges to be angry with everything around him, but not Bret. He walked in that school with so much confidence, joy and happiness, that he greeted the entire class with a big “hi, Me Bret”, and hugged everyone in the room. It was from that moment on when they all realized what a special young man he was. There wasn’t a mean bone in his body. He just exuded love and compassion to everyone he met.
Bret continued to thrive for the next 5 years or so. Throughout that time, we had occasional hospital stays for one thing or another, as well as routine scans and blood tests, but against all odds, he remained in a stable condition. Our happier days quickly came to a halt in late November of 2011. We started to notice subtle changes with his vision, like not being able to focus, depth perception and an increase in seizures. As these signs worsened, we discovered a lump on the back of his head and immediately called his doctors. His routine scan was moved up and completed in January of 2012. Our worst fear had come true, another brain tumor. A biopsy a few days later revealed that this was a post-radiation tumor called a Chondroblastic Osteosarcoma, one that we knew he had a 20% risk of developing from his treatments the first time around.
We again were faced with all of our options for Bret and were advised by his doctors that given how he was unable to tolerate the treatments the first go –around, they did not want to put him through that trauma again. So we were forced to make the decision that no parent should ever have to make. We wanted to give our son the best quality of life he had remaining and to make sure he was as comfortable as possible. The doctors had expected it to be 2 to 3 months left, but once again, Bret did things his own way and fought until the very end. On May 25, 2012, our courageous young boy lost his fight and passed away so very peacefully.
Bret was truly a “Miracle Boy” in everyway imaginable. The doctors never thought that he would have survived another 9 1⁄2 years, so this is how he was commonly referred to every time we were there. Throughout his entire journey, he never once let you know that he was in pain, or that he was angry or sad about having cancer. He always made sure to tell us “Love You More” many times throughout the day. He has touched so many lives and continues to inspire people everywhere with his strength, courage, love and compassion, that it is why we were driven to start The Bret Laczynski Brain Cancer Research Fund in his honor. It is what Bret would have wanted to help in whatever way he could, so no child should ever have to suffer like he did. It is with great pride that I can call him my son and will continue to keep his memory alive. “Thumbs Up” Bret and “We Love You, We Love You More”!

There needs to be a lot more research for clinical trials for kids with Medulloblastoma 🩶🎗️
11/11/2026

There needs to be a lot more research for clinical trials for kids with Medulloblastoma 🩶🎗️

MEDULLOBLASTOMA:
A headache that doesn't go away. Repeated vomiting. A child who suddenly struggles to walk or maintain balance. Sometimes, these are more than ordinary childhood symptoms.

For some children, the diagnosis is Medulloblastoma, an aggressive brain tumor that requires urgent, carefully coordinated treatment.

Behind every diagnosis is a child whose life should be filled with school, games, and childhood dreams. And behind every treatment decision is a medical team working to protect not only that child's life, but also their future development.

Let's understand this disease and the important role of modern radiation therapy in its management.

1. WHAT IS MEDULLOBLASTOMA?

Medulloblastoma is a malignant embryonal tumor of the central nervous system (CNS) and one of the most common malignant brain tumors in children.

It typically originates in the cerebellum, the part of the brain responsible for coordination, balance, and motor control.

It is particularly common in young children, although it can occur at any age.

Unlike many other brain tumors, medulloblastoma has an important tendency to spread through the cerebrospinal fluid (CSF).

This means that tumor cells can travel from the primary tumor site and implant along the surfaces of the brain and spinal cord, producing what is known as leptomeningeal dissemination or drop metastases.

In some patients, metastatic deposits may be found along the spinal canal, making assessment of the entire craniospinal axis essential.

2. CLINICAL PRESENTATION: WHAT SHOULD WE LOOK FOR?

Symptoms are often related to increased intracranial pressure, cerebellar dysfunction, or obstruction of normal CSF circulation.

Common clinical presentations include:

- Persistent headaches, particularly in the morning.
- Nausea and recurrent vomiting.
- Unsteady walking and loss of balance (ataxia).
- Difficulty with coordination.
- Double vision or abnormal eye movements.
- Fatigue and changes in behavior.
- In some cases, hydrocephalus due to obstruction of the fourth ventricle.

Because the tumor frequently develops near the fourth ventricle, it can interfere with normal CSF circulation, leading to obstructive hydrocephalus.

3. UNDERSTANDING THE MOLECULAR SUBGROUPS

Medulloblastoma is not a single biological disease.

Modern molecular classification identifies four major molecular groups:

1. WNT-Activated Medulloblastoma

This subgroup generally has a favorable prognosis compared with the other major groups when treated appropriately.

2. SHH-Activated Medulloblastoma

Associated with abnormalities in the Sonic Hedgehog signaling pathway. Its clinical behavior varies according to age and additional molecular features, including TP53 status.

3. Group 3 Medulloblastoma

Often associated with MYC amplification in a subset of cases and generally considered biologically aggressive.

4. Group 4 Medulloblastoma

A common molecular subgroup with variable clinical behavior and a distinct pattern of genetic alterations.

These molecular subgroups are important because they help clinicians understand tumor biology, estimate prognosis, and develop more individualized treatment strategies.

4. HOW IS MEDULLOBLASTOMA DIAGNOSED?

Accurate diagnosis and staging are essential before treatment begins.

The diagnostic workup generally includes:

MRI Brain with Contrast

Used to identify the primary tumor, evaluate its relationship with surrounding structures, and assess possible hydrocephalus.

MRI of the Entire Spine

Essential for evaluating possible leptomeningeal dissemination and spinal drop metastases.

Histopathological Examination

Confirms the diagnosis and identifies the histological subtype, such as classic, desmoplastic/nodular, or large-cell/anaplastic medulloblastoma.

Molecular Testing

Helps identify the molecular subgroup and relevant genetic alterations.

CSF Cytology

Used to detect tumor cells in the cerebrospinal fluid when clinically appropriate. Its timing is important, and sampling is generally performed after surgery when it is safe to do so.

Disease dissemination is also assessed using the Chang M staging system, which describes the extent of metastatic spread.

5. HOW IS MEDULLOBLASTOMA TREATED?

Treatment requires a multidisciplinary approach involving pediatric neurosurgery, pediatric oncology, radiation oncology, medical physics, radiology, and pathology.

The main treatment modalities are:

A. SURGERY

The initial treatment usually involves maximal safe surgical resection.

The objectives are to obtain tissue for diagnosis, remove as much tumor as safely possible, and relieve pressure on surrounding structures.

However, complete removal should never come at the expense of unacceptable neurological injury, particularly when the tumor is closely associated with the brainstem or critical structures.

B. CHEMOTHERAPY

Chemotherapy is an essential component of treatment for many children.

Common agents include:

- Cisplatin.
- Vincristine.
- Cyclophosphamide.
- Lomustine (CCNU).

The exact regimen depends on the patient's age, risk group, molecular findings, and treatment protocol.

C. RADIOTHERAPY

This is one of the most important components of treatment for many children with medulloblastoma, particularly those old enough to receive craniospinal irradiation.

And unlike many other localized brain tumors, treating only the primary tumor may not be sufficient because medulloblastoma can spread through the CSF.

This brings us to one of the most important concepts in pediatric radiation oncology.

6. WHY IS CRANIOSPINAL IRRADIATION (CSI) SO IMPORTANT?

Craniospinal Irradiation is a specialized radiation technique designed to treat the entire subarachnoid space surrounding the brain and spinal cord.

Its purpose is to treat both the primary disease region and potential microscopic tumor dissemination throughout the CSF pathways.

CSI generally includes:

- The entire brain.
- The meninges and intracranial CSF spaces.
- The spinal canal and spinal CSF spaces.
- The appropriate spinal and vertebral treatment volume according to the patient's skeletal maturity and treatment protocol.

After CSI, an additional radiation dose, known as a Boost, is delivered to the primary tumor bed.

Selected patients with visible metastatic deposits may also require additional boosts to those sites.

7. RADIOTHERAPY DOSES: AVERAGE-RISK VS HIGH-RISK

Radiotherapy doses are determined by the patient's clinical and biological risk classification.

For children generally older than 3–4 years, depending on the protocol:

Average-Risk Medulloblastoma

A commonly used approach includes:

- CSI: 23.4 Gy in 13 fractions.
- Tumor bed boost: Additional 30.6 Gy.
- Total primary-site dose: 54 Gy.

High-Risk Medulloblastoma

A commonly used approach includes:

- CSI: 36 Gy in 20 fractions.
- Tumor bed boost: Additional 18–19.8 Gy.
- Total primary-site dose: 54–55.8 Gy.

These are representative treatment schedules, not universal prescriptions. Specific protocols may modify the doses, target volumes, and boost strategy according to metastatic status, histology, molecular features, and treatment response.

8. WHY IS AGE SO IMPORTANT IN PEDIATRIC MEDULLOBLASTOMA?

One of the greatest challenges in treating young children is balancing tumor control with the long-term effects of radiation.

The developing brain is particularly sensitive to radiation exposure.

Children younger than approximately 3 years are often managed with radiation-sparing strategies, initially using surgery and chemotherapy to delay or sometimes avoid radiotherapy.

However, this is not an absolute rule.

The decision depends on the molecular subgroup, histology, disease dissemination, response to chemotherapy, and the child's neurological development.

The ultimate goal is to achieve disease control while reducing the risk of long-term neurodevelopmental complications.

9. MODERN RADIOTHERAPY TECHNIQUES AND TREATMENT PLANNING

Delivering CSI in children is technically challenging.

The treatment field must cover the entire craniospinal axis while maintaining appropriate dose uniformity and minimizing exposure to healthy organs.

Modern treatment techniques include:

3D Conformal Radiotherapy (3D-CRT)

Traditionally used for craniospinal irradiation, with careful management of field junctions and dose distribution.

Intensity-Modulated Radiation Therapy (IMRT)

Allows modulation of radiation intensity to improve dose conformity and protect selected organs at risk.

Volumetric Modulated Arc Therapy (VMAT)

Can provide highly conformal treatment through rotational delivery and may help manage complex craniospinal target volumes.

Proton Therapy

Protons offer a major dosimetric advantage in selected pediatric patients because of their characteristic Bragg peak and reduced exit dose.

This can reduce unnecessary radiation exposure to healthy tissues outside the target volume, which is particularly relevant in children expected to survive for many years.

However, proton therapy requires careful consideration of range uncertainty, robustness, and treatment geometry.

10. ORGANS AT RISK: PROTECTING THE CHILD'S FUTURE

During CSI planning, several organs require particular attention:

- Cochleae: To reduce the risk of radiation-associated hearing impairment.
- Thyroid gland: To reduce the risk of hypothyroidism.
- Heart and lungs: Especially during spinal treatment.
- Esophagus and bowel: Depending on the treatment technique and field arrangement.
- Kidneys: Particularly relevant to posterior spinal field arrangements.
- Pituitary and hypothalamus: Important for long-term endocrine function.
- Developing vertebral bodies: To reduce the risk of asymmetric growth.
- Brain and healthy neural structures: To minimize long-term neurocognitive effects.

Long-term follow-up is essential because survivors may experience hearing impairment, endocrine dysfunction, growth abnormalities, neurocognitive difficulties, or secondary malignancies.

11. WHAT IS THE ROLE OF THE RADIATION THERAPIST?

Behind every successful treatment delivery is a team responsible for accuracy and patient safety.

For pediatric medulloblastoma, the radiation therapist plays a particularly important role in:

- Reproducible patient positioning.
- Immobilization using an appropriate thermoplastic mask.
- Accurate daily setup and image verification.
- Monitoring treatment-field alignment and field junctions.
- Maintaining patient comfort and safety.
- Supporting children who may feel frightened or anxious during treatment.

Treating a child requires more than technical precision.

It requires patience, communication, and an understanding that every treatment session may be a completely new experience for a young patient.

Medulloblastoma is an aggressive childhood brain tumor, but advances in neurosurgery, chemotherapy, molecular classification, and modern radiation therapy have significantly improved treatment outcomes.

Craniospinal irradiation remains a cornerstone of treatment for many eligible children because the disease has the ability to spread through the cerebrospinal fluid.

But our responsibility goes beyond controlling the tumor.

We must protect the developing brain, preserve hearing, minimize late effects, and give every child the best possible chance of returning to a normal childhood.

WE ARE NOT JUST TREATING A BRAIN TUMOR. WE ARE PROTECTING A CHILD'S FUTURE.
❤️☢️

---

SCIENTIFIC REFERENCES

1. National Cancer Institute (NCI). Childhood Medulloblastoma and Other CNS Embryonal Tumors Treatment (PDQ®) – Health Professional Version.

2. SIOP-Europe and European Reference Network. Medulloblastoma therapy: Consensus treatment recommendations. European Journal of Cancer Paediatric Oncology. 2024.

3. National Comprehensive Cancer Network (NCCN). Pediatric Central Nervous System Cancers, Version 2.2025.

4. The Royal College of Radiologists. Radiotherapy Dose Fractionation, 4th Edition. 2024.

5. World Health Organization. WHO Classification of Tumours of the Central Nervous System, 5th Edition.

Some Promising News 🩶🎗️
11/06/2026

Some Promising News 🩶🎗️

Researchers have discovered a surprising growth pattern in glioblastoma, one of the most aggressive and difficult-to-treat brain cancers.

💔
10/28/2026

💔

No One Knows The Trials and Tribulations Of a Special Needs Parent, Unless You’re Dealing With it Yourself.I Thank God E...
10/22/2026

No One Knows The Trials and Tribulations Of a Special Needs Parent, Unless You’re Dealing With it Yourself.
I Thank God Everyday For Choosing Me To Be Bret’s Mom 💛🎗️🩶

10/16/2026

📺 Happy National I Love Lucy Day! ❤️

Lucy and Ethel thought keeping up with chocolates was hard… try keeping up with a childhood cancer medication schedule! 💊😂

Between medications, appointments, and everything in between, sometimes all you can do is laugh at the chaos!

Because if there’s one thing cancer parents understand, it’s that the conveyor belt NEVER stops! 🎗️💛

💛🎗️🩶
10/01/2026

💛🎗️🩶

DAY 30 OF PEDIATRIC CANCER AWARENESS MONTH 💛🎗️🩶It’s Not Just A Month For These Kids, It’s A Lifetime.  PLEASE Don’t Forg...
09/30/2026

DAY 30 OF PEDIATRIC CANCER AWARENESS MONTH 💛🎗️🩶

It’s Not Just A Month For These Kids, It’s A Lifetime. PLEASE Don’t Forget 💛🎗💛🎗💛🎗💛🎗💛

09/29/2026

Address

Atlanta, GA

Alerts

Be the first to know and let us send you an email when Bret Laczynski Brain Cancer Research Fund posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Nearby gyms & sports facilities